Following a new Cardinal Health survey on biosimilars in rheumatology, Cardinal Health's VP of biosimilars shared how she plans to use the survey findings as a jumping off point for Cardinal Health (with its manufacturing partners) to improve biosimilar education and engage the rheumatology community.
We are at an interesting time in this industry as it relates to biosimilar competition and education. The EU and U.S. are now learning together how to encourage uptake of the curative oncology biosimilars. This raises two questions around what types of data have and will play crucial future roles for improving confidence in your biosimilar.
As you can imagine, getting established as a biotech boasting a unique expression system comes with its own set of challenges — especially when trying to enter a nascent biotech space in an emerging market. Here, one CEO discusses the strategies his company is exploring to gain buy-in on the company’s long-term goals in South Africa.
Many of the articles on this site are focused on how manufacturers can or are working to improve biosimilar uptake. But other stakeholders are aware of the power they, too, hold in improving uptake. One oncologist highlights how she and fellow oncologists are educating stakeholders and drawing greater government attention to payer policy and biosimilar use.
To better understand the payer dynamics taking shape in the increasingly competitive oncology space, I spoke with Biosimilar Development editorial advisory board member Kathy Oubre. Here, she highlights the changing dynamics she is observing on the payer front and shares the impact these can have on oncology practices and oncologists’ overall use of biosimilars.
Following publication of his recent white paper, I touched base with Alex Brill to better visualize what a shared savings program might look like for biosimilars and to unpack the questions and challenges facing CMMI in establishing such a program.
In this Q&A, one rheumatologist talks through some of the biggest takeaways he had from a recent Cardinal Health survey and how rheumatologists, manufacturers, and payers can better move the biosimilar industry forward for patients.
The (re)emergence of small biotechs in the biosimilar world has caught my eye in the last year. I sat down (virtually) with the CEO of one such company, BiosanaPharma, to discuss the advantages and challenges of being a virtual biotech pursuing biosimilar and novel biologic development.